Animal model of supportive therapy for tumor patients

Oncology supportive therapy is a comprehensive treatment that focuses on treating the patient as a whole and controlling the various symptoms that occur clinically, which can effectively improve the patient's physical and mental state, quality of life, and even the patient's outcome. Supportive therapy aims to ameliorate the adverse reactions of oncology patients during chemotherapy and to prevent chemotherapy dose reductions and scheduling delays, which include pain, thrombocytopenia, neutropenia, and so on. Cancer supportive therapy has rapidly become an area of interest in medicine and drug development, but preclinical studies have not been sufficiently emphasized. Through systematic in-depth research and understanding of the toxicity associated with chemotherapy, radiation, targeted, and immunotherapy and the biological environment of tumors, CIR Biopharma is committed to developing preclinical animal models that can be directly applied to supportive care for cancer patients. The platform is under construction and expansion, and currently includes radiation therapy or chemotherapy-induced oral mucositis, dermatitis, proctitis, gastrointestinal mucositis, chemotherapy-induced diarrhea (CID), and bone marrow suppression.